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Abstract
Objective: To determine the frequency and patterns of acquired antiretroviral drug resistance in a rural primary health care
programme in South Africa.
Design: Cross-sectional study nested within HIV treatment programme.
Methods: Adult ($18 years) HIV-infected individuals initially treated with a first-line stavudine- or zidovudine-based
antiretroviral therapy (ART) regimen and with evidence of virological failure (one viral load .1000 copies/ml) were enrolled
from 17 rural primary health care clinics. Genotypic resistance testing was performed using the in-house SATuRN/Life
Technologies system. Sequences were analysed and genotypic susceptibility scores (GSS) for standard second-line regimens
were calculated using the Stanford HIVDB 6.0.5 algorithms.
Results: A total of 222 adults were successfully genotyped for HIV drug resistance between December 2010 and March
2012. The most common regimens at time of genotype were stavudine, lamivudine and efavirenz (51%); and stavudine,
lamivudine and nevirapine (24%). Median duration of ART was 42 months (interquartile range (IQR) 32–53) and median
duration of antiretroviral failure was 27 months (IQR 17–40). One hundred and ninety one (86%) had at least one drug
resistance mutation. For 34 individuals (15%), the GSS for the standard second-line regimen was ,2, suggesting a
significantly compromised regimen. In univariate analysis, individuals with a prior nucleoside reverse-transcriptase inhibitor
(NRTI) substitution were more likely to have a GSS ,2 than those on the same NRTIs throughout (odds ratio (OR) 5.70, 95%
confidence interval (CI) 2.60–12.49).
Conclusions: There are high levels of drug resistance in adults with failure of first-line antiretroviral therapy in this rural
primary health care programme. Standard second-line regimens could potentially have had reduced efficacy in about one in
seven adults involved.
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Introduction
South Africa has the largest HIV burden in the world, with an
estimated 5.6 million people living with HIV [1]. The past eight
years have seen massive scale-up of antiretroviral therapy (ART) in
the country, which has substantially reduced population-level
mortality and increased life expectancy [2,3]. However, the
number of people newly infected with HIV each year continues to
exceed the number accessing ART [1]. In this context, anti-
retroviral drug resistance is a potential threat to the control of HIV
[4].
South Africa follows the public health approach to ART
delivery with standardised drug regimens and simplified decision-
making, with the inclusion of routine viral load monitoring for the
detection of treatment failure [5]. Viral load monitoring should
enable early identification of treatment failure and, where
appropriate, switch to second-line regimens. This has been shown
to improve survival and health [6,7]. Delay in switching to second-
line therapy and prolonged viraemia compromise the response to
standardised second-line regimens [8–11].
The majority of studies from South Africa focused on acquired
drug resistance (resistance to one or more drugs in an individual
who has been treated with antiretroviral therapy) have been
conducted in urban, hospital-based treatment programmes [12–
23]. There is a critical need for data from programmes in rural
South Africa (distinction between urban and rural as defined by
the South African Population Census 2011) [24], as there are
many challenges unique to rural communities, and rural health
systems remain critically under-resourced [25]. Here, we present
data from a large, decentralised, primary health care HIV
treatment programme in rural KwaZulu-Natal.
Methods
Ethics Statement
The study was approved by the Biomedical Research Ethics
Committee of the University of KwaZulu-Natal (ref. BF052/10)
and the Health Research Committee of the KwaZulu-Natal
Department of Health (ref. HRKM 176/10). Written informed
consent was obtained from all the study participants.
Setting
The Hlabisa HIV Treatment and Care Programme is a
decentralised, primary health care (PHC) programme in the
predominantly rural Hlabisa health sub-district in northern
KwaZulu-Natal. Details of the programme have been reported
previously [26,27]. HIV treatment and care is delivered at 17
primary health care clinics and one district hospital and is largely
provided by nurses and counsellors, with weekly or fortnightly
visits by a medical officer. All treatment and care is provided free
of charge. The programme was supported from 2004 to 2012 by
the US Agency for International Development (USAID) through
the President’s Emergency Plan for AIDS Relief (PEPFAR).
The programme adheres to the national antiretroviral treatment
guidelines [28,29]. From the inception of the programme in 2004
until early 2010, first-line ART regimens were stavudine (d4T),
lamivudine (3TC), and either efavirenz (EFV) or nevirapine
(NVP). Viral load was measured every six months (repeated after
three months if .5000 copies/ml), and a switch to second-line
therapy was recommended if two consecutive viral loads (VL) were
.5000 copies/ml despite good (.80%) adherence. Substitution of
zidovudine (AZT) for d4T was allowed in the event of treatment-
limiting toxicity [28]. In 2010, the frequency of VL monitoring
was modified: measurement at month 6, month 12, then every 12
months if VL ,400 copies/ml. Viral load .1000 copies/ml
prompted repeat measurement after three months (including
intensive adherence counselling) and the threshold for switch to
second-line regimen was changed to two consecutive viral loads
.1000 copies/ml. Tenofovir (TDF) also replaced d4T in first-line
regimens and was available for substitution for individuals
experiencing toxicity with d4T or AZT [29].
Study Design
This was a cross-sectional study enrolling HIV-infected adults
with virological failure on first-line antiretroviral therapy. Inclu-
sion criteria were: adult ($18 years); initiated on first-line d4T- or
AZT-based regimen; received treatment for at least 12 months;
and evidence of virological failure (defined for the purposes of this
study as one viral load .1000 copies/ml). Exclusion criteria were:
prior use of nucleoside reverse transcriptase inhibitor (NRTI)
monotherapy or dual therapy (not including regimens for the
prevention of mother-to-child transmission (pMTCT)), prior
protease inhibitor (PI) use, and initiated on first-line TDF-based
regimen. The decision to include only those who commenced
treatment with d4T- or AZT-based regimens, and exclude those
who initiated TDF-based regimens, was primarily to allow formal
comparison with other studies in the region.
Individuals were recruited at all 17 PHC clinics between
December 2010 and March 2012. There were two possible routes
for enrolment: i) Routine clinic - adults with virological failure
(latest VL .1000 copies/ml) were identified by clinic staff during
routine visits and referred to the physician for review; ii) virological
failure camp – eligible adults were proactively identified through
the programme’s operational database, were contacted by
programme staff, and were booked for physician review on a
specific day at their regular clinic. In both models, the physician
performed a clinical evaluation and obtained written informed
consent for the study. A 5 ml EDTA whole blood sample for HIV
drug resistance genotyping was collected during the clinical
evaluation. Basic clinical and demographic data were collected
on a standardised clinical form in parallel to the records in the
Africa Centre’s ART Evaluation and Monitoring System (ARTe-
mis), an operational database holding treatment and laboratory
monitoring information. The clinical information was entered in
anonymised form into a relational database, the SATuRN REGA
database [30].
Genotypic Resistance Testing
Specimens were transported daily from the clinics to the Africa
Centre and the same day to the Africa Centre laboratory in
Durban (200 km from site). At the laboratory, plasma was
aliquoted and stored at 280uC until sequenced. Samples were
sequenced within a week of collection. HIV RNA was extracted
using the QIAMP RNA extraction kit (Invitrogen) modified to
extract RNA from 200 ml of plasma instead of 140 ml, to
concentrate the viral RNA for better amplification rates.
A previously described in-house HIV-1 drug resistance
genotyping method was used to genotype the samples [31–33].
Briefly, the extracted RNA was reverse transcribed using the
Superscript III 1st strand synthesis kit (Life Technologies, Foster
City, CA) followed by nested PCR using Platinum Taq polymerase
(Life Technologies, Foster City, CA). Successful PCR amplifica-
tion was assessed using 1% agarose gel (Bioline, Taunton,
Massachusetts) electrophoresis run at a 100 V for 40 minutes.
The PCR products were cleaned up using the PureLink QUICK
PCR Purification Kit (Life Technologies, Foster City, CA) and
sequenced using the Big Dye Terminator kit ver3.1 (Life
Technologies, Foster, City) and a set of four bidirectional primers.
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Capillary sequencing electrophoresis was done on 3130Xl Genetic
Analyzer (Life Technologies, Foster, CA).
The sequences covering all of the 99 protease codons and the
first 300 codons of the reverse transcriptase region were assembled
using Geneious Pro genetic analyzer [34]. The quality of the
sequences was assessed using the HIV-1 Quality Analysis Tool
[35] and the Calibrated Population Resistance (CPR) tool [36].
HIV-1 subtyping was performed using the REGA HIV-1
Subtyping Tool v 2.0 [37]. Phylogenetic analysis was done to
aid with quality assurance of the sequencing. The sequences were
aligned to a reference dataset of HIV-1 subtype C that included
other sequences previously sampled in KwaZulu-Natal and
sequences from other geographic regions (n .1000) available
from public HIV sequence databases. Phylogenies were con-
structed using neighbour-joining (NJ), maximum likelihood (ML)
and Bayesian methods. Reliability of the trees was assessed by
bootstrap methods (1000 replicates) for NJ and ML. Posterior
probabilities were calculated from a sample of 10 000 trees
sampled over 16107 generations to determine the reliability of
Bayesian trees. Trees were visualized using FigTree (http://tree.
bio.ed.ac.uk/software/figtree). All the sequences generated for this
manuscript are available from Genbank with accession numbers
KC951632–KC951853.
The method was validated in using a panel of proficiency testing
samples obtained from the French National Agencies for Research
on AIDS and Viral Hepatitis (ANRS). The panel was analysed
using the in-house method and the United States food and drugs
Agency (FDA) approved Viroseq genotyping method in parallel.
The laboratory participates in the Quality Control for Molecular
Diagnostics (QCMD) proficiency testing programme, and receives
one EQA panel per year. This validated method is an open access
and discounted method, with reagent costs of about US$50, made
available by a partnership between SATuRN and Life Technol-
ogies to laboratories in Africa. All resistance results were provided
within 15 days to the physician and were used for clinical
management.
Data Analysis
The sequence data were linked to the clinical and demographic
data in the SATuRN REGA database. The interpretation of drug
resistance data from the nucleotide sequences was done using the
Stanford HIVSeq algorithm version 6.0.5 [38]. Genotypic
susceptibility scores (GSS) were calculated, also using the Stanford
HIVSeq algorithm version 6.0.5, for each antiretroviral agent and
then a total score was calculated for the standard second-line
regimens. This was done to assess the impact of observed drug
resistance mutations on the predicted effectiveness of standard
second-line regimens. Total GSS for the standard second-line
regimen was calculated depending on the patient’s treatment
history: for participants on d4T or AZT at the time of genotyping,
GSS was calculated for a regimen of TDF, 3TC and lopinavir/
ritonavir (LPVr); whilst for those on TDF at the time of
genotyping, GSS was calculated for a regimen of AZT, 3TC
and LPVr. These standard second-line regimens were consistent
with the recommendations in the current national ART guidelines
[29]. For the purposes of this analysis, compromised second-line
regimen was defined as GSS,2.
Age was defined as at the date of enrolment. Baseline CD4+ cell
count was defined as the CD4+ cell count closest to but prior to
the date of ART initiation. CD4+ cell count and viral load at time
of genotype were the measurements closest to but prior to the date
of genotype. Immunological failure was defined according to
WHO guidelines: fall of CD4+ cell count to baseline or below;
50% fall from on-treatment peak value; or persistent CD4+ cell
count below 100 cells/ml [39]. Duration of antiretroviral failure
was estimated from the date of the first viral load .1000 copies/
ml to date of genotype, unless there was a viral load ,50 copies/
ml in-between in which case the time was estimated from the next
viral load .1000 copies/ml. If there was no viral load #1000
copies/ml then time was calculated from date of ART initiation.
All statistical analyses were performed using STATA version
11.2 (StataCorp, College Station, Texas). Descriptive statistics
were used to summarise the baseline demographic and clinical
characteristics. Frequency distributions of specific mutations were
calculated. Logistic regression was used to explore factors
associated with a compromised second-line regimen (GSS,2).
The variables used for regression analysis included demographic
characteristics (age and sex), laboratory results (CD4+ cell count
and viral load), and treatment information (regimen, ART
substitutions, duration of treatment).
Results
A total of 260 individuals with virological failure on first-line
ART were enrolled between December 2010 and March 2012.
Samples from 242 (93%) of the patients were successfully
genotyped and 222 (85%) were included in the analysis
(Figure 1). All the 222 patients were infected by HIV-1 subtype
C viruses. Of the 222 patients, 160 (72%) were women, and the
median age was 37 years (IQR 32–44). One hundred and twenty-
four (56%) were enrolled through the virological failure camp
system, and 98 (44%) through the routine clinic system. The two
enrolment groups did not differ substantially in sex, age, baseline
CD4+ cell count, time on ART, time on failing regimen, or history
of drug switch. Details of the demographic and clinical character-
istics are summarised in Table 1.
Median duration of ART was 42 months (IQR 32–53) and
median duration of antiretroviral failure was 27 months (IQR 17–
40). One hundred and thirty four (60%) had achieved virological
suppression (VL,1000 copies/ml) on at least one occasion prior
to genotyping, but only 89 (40%) had achieved VL,50 copies/ml.
Two hundred (90%) of the patients had two or more viral loads
.1000 copies/ml before genotyping and the median number of
viral loads .1000 copies/ml before genotyping was 3 (IQR 2–5).
During therapy, 81 (36%) had one or more drug substitution, the
majority of which were NRTI substitutions. At the time of
genotype, 75 (34%) had evidence of immunological failure,
according to WHO definitions.
One hundred and ninety one (86%) individuals had at least one
drug resistance mutation at the time of genotyping: 181 (82%) had
NNRTI resistance mutations and 179 (81%) had NRTI resistance
mutations (Figures 2 and 3). M184V mutation was the most
common mutation, detected in 173 (78%) patients. The K103N/S
mutation was the most common NNRTI mutation, detected in
101 (45%) patients. Thymidine analogue mutations (TAMs) were
detected in 88 (40%) of the patients and 39 (18%) had three or
more TAMs (Figure 3). The K65R mutation was identified in 13
(6%) patients, of which eight were on TDF at the time of
genotyping. The Q151M complex (Q151M, V75I, F77L and
F116Y) was detected in 3 (1%) patients. One of these patients had
the Q151M complex and K65R, resulting in high-level resistance
to all NRTIs.
Thirty-four individuals (15%) had a calculated GSS ,2 for the
standard, guideline-recommended second-line regimen, suggesting
a potentially compromised regimen. Five of these had a GSS of 1,
suggesting that only the protease inhibitor would have full activity
in the standard second-line regimen. The majority had a GSS of 2
(n = 143, 64%). Logistic regression was used to identify factors
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associated with compromised second-line regimen, defined as GSS
,2 (Table 2). In univariate analysis, there was strong evidence that
individuals with a prior NRTI substitution were more likely to
have a GSS ,2 than those maintained on the same NRTIs
throughout (OR 5.70, 95% CI 2.60–12.49). There was weak
evidence that males were more likely to have GSS ,2 than
females (OR 1.84, 95%CI 0.85–3.99). There was insufficient
power to explore multivariable models given the limited number
with GSS ,2.
Discussion
This study assessed the levels of acquired drug resistance in
adults with virological failure on first-line ART in a rural primary
health care treatment programme. This is one of the largest adult
drug resistance studies to date in South Africa and the first to focus
on a single rural treatment programme. In common with other
studies from South Africa, almost all individuals with virological
failure on first-line ART had evidence of antiretroviral drug
resistance. In the context of public health antiretroviral strategies
based on standardised first- and second-line regimens, it is
important to explore how drug resistance impacts not only on
individual antiretroviral drugs but also on drug regimens. Of
concern was the fact that one in seven of these adults had complex
resistance patterns with the potential to limit the efficacy of the
standard second-line ART regimen. Of equal concern were the
long periods of time on failing regimens despite the use of viral
load monitoring, which suggest critical deficiencies in programme
quality.
It has been well documented that prolonged failure on first-line
regimens leads to the accumulation of drug resistance and to
poorer outcomes on second-line therapy [8–10]. In this study we
found 15% had three or more TAMs and 1% had the Q151M
complex, patterns known to develop during long periods on a
failing regimen [40,41]. The presence of three or more TAMs
(inclusive of M41L or L210W) significantly reduces the activity of
TDF and thus a standard second-line regimen of TDF/3TC/
LPVr might have suboptimal efficacy [42]. The proportions of
TAMs reported here are broadly similar to those from hospital-
based programmes in Johannesburg and Durban [17,20,22].
Conversely, they are higher than reported from the Western Cape,
from Soweto and a workplace programme in Johannesburg
[15,16,18,21]; however, it should be noted that in two of those
studies the threshold for definition of virological failure and for
genotyping was lower at a single viral load .400 copies/ml
(Table 3) [15,21]. Although our definition was a single viral load
.1000 copies/ml, almost all cases had two or more consecutive
viral loads above this threshold prior to genotyping and so would
have been eligible for a switch to second-line therapy according to
national guidelines.
The K65R mutation was present in 6% of cases, although over
half of these were on TDF at the time of genotyping, due to
previous substitution from d4T or AZT. There is evidence that
K65R develops more frequently in subtype C viruses, primarily
due to a difference in the template nucleotide sequence [43,44].
K65R confers high-level resistance to TDF and its presence during
failure of d4T-based treatment would therefore also compromise
the activity of the standard second-line regimen.
Surprisingly, duration on ART and duration on failing regimen
were not associated with more complex resistance patterns in this
study population. This may partly be due to lack of statistical
power but also potentially to the complex relationship between
adherence and resistance [45]. The only adherence data available
was the data in the clinical records collected using standard
adherence assessment tools, as contained within the national ART
guidelines [29]. However, the poor performance of self-reported
adherence measurements has been previously reported from this
programme [46]. About one in four individuals had a history of
NRTI substitution, most commonly from stavudine to zidovudine.
The observation that this was associated with GSS,2 may reflect
the effect of poorer adherence due to debilitating long-term
toxicities, such as peripheral neuropathy and lipodystrophy
syndrome, with consequent accumulation of resistance in this
subgroup. Furthermore, single drug substitutions could have
occurred in the absence of viral suppression (or absence of recent
viral load), thus compromising the modified regimen.
Figure 1. Flow chart showing patients excluded from analysis. Of the 20 excluded patients, 17 were initiated on TDF-based first-line therapy,
dual NRTI therapy or were already receiving a second-line regimen at time of genotype. The three protocol violations were: two patients on
treatment for less than a year, and one with viral load ,1000 copies/ml at the time of genotyping.
doi:10.1371/journal.pone.0072152.g001
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In this high prevalence community, there has been rapid scale-
up of ART over the past eight years and high levels of ART
coverage have been achieved in the community [27,47,48]. In this
context and with on-going high incidence in the area [49], the
high levels of acquired drug resistance give rise to the potential for
transmitted drug resistance, although to date we have found no
evidence of transmitted antiretroviral resistance in this community
[31]. Prior to this study, despite more than 18 000 adults having
started ART and relatively high rates of virological failure,
remarkably few people (fewer than 50) had been switched to
second-line regimens. This study was implemented not only to
assess the levels and patterns of drug resistance but also to aid
clinical management, and to focus attention and improve
awareness of these issues within the programme. The compre-
hensive format for reporting resistance results with management
recommendations to the clinic also provided a useful training tool
for junior physicians, nurses and counsellors.
The national antiretroviral treatment guidelines recommend
routine viral load monitoring to identify virological failure.
However, if the results are not appropriately acted on and
individuals are maintained on failing regimens, there may be
accumulation of further resistance and progression to immunolo-
gical and clinical failure. In this study, the period of time spent on
failing first-line regimens was excessively long. Similar findings of
prolonged viraemia have recently been reported from a multi-
centre programme in Johannesburg [50]. Conversely, the IeDEA-
Southern Africa collaboration reported a median delay of 4.6
months between identification of virological failure and switch to
second-line therapy [51]. The five cohorts included in that analysis
were mostly physician-led and well-resourced, hospital based
programmes, which might not be representative of most South
African programmes. There is clearly a need for more stringent
adherence to the current monitoring guidelines and continued
training of health care workers, but also a need to understand the
programmatic factors that contribute to our findings. The priority
both from the Department of Health and the funding agencies
providing support in this area has understandably been initiation
of ART for eligible individuals but as a result there has been much
less effort directed at support and maintenance of people on
lifelong ART [52]. The National Strategic Plan for 2012–2016
does highlight the need for ‘strengthening quality standards and
adequate monitoring of drug resistance’ although it is notable that
there is no explicit mention of monitoring virological outcomes in
the monitoring and evaluation framework [53].
Health systems, particularly in rural areas, have been put under
huge strain by the rapid scale-up of HIV testing, treatment and
care. There is already evidence from South Africa that the quality
of treatment programmes has declined as systems have become
more stretched [54,55]. One study in particular from Cape Town
demonstrated an increasing risk of virological failure with each
Table 1. Demographic and clinical characteristics.
Characteristic
Sex, n (%)
Female 160 (72%)
Age, years
Median (IQR) 37 (32–44)
18–24 8 (4%)
25–34 69 (31%)
35–44 94 (42%)
$45 51 (23%)
Baseline CD4+ cell count, cells/mla
Median (IQR) 108 (50–169)
,50 48 (25%)
50–100 41 (21%)
101–200 88 (45%)
.200 17 (9%)
CD4+ cell count at time of genotype, cells/ml
Median (IQR) 221 (124–322)
,50 16 (7%)
50–100 29 (13%)
101–200 54 (24%)
.200 123 (55%)
Immunological failure at time of genotype, n (%)b 75 (34%)
Viral load at time of genotype, log10 copies/ml
Median (IQR) 4.25 (3.68–4.83)
Time between last viral load and genotype, months
Median (IQR) 3.3 (1.5–6.0)
Ever achieved virological suppression, n (%)
Viral load ,1000 copies/ml 134 (60%)
Viral load ,50 copies/ml 89 (40%)
Duration of antiretroviral therapy, months
Median (IQR) 42 (32–53)
Duration of antiretroviral failure, monthsc
Median (IQR) 27 (17–40)
Initial antiretroviral regimen, n (%)
d4T/3TC/EFV 156 (70%)
d4T/3TC/NVP 64 (29%)
AZT/3TC/EFV 2 (1%)
Antiretroviral regimen at time of genotype, n (%)
d4T/3TC/EFV 114 (51%)
d4T/3TC/NVP 53 (24%)
AZT/3TC/EFV 19 (8%)
AZT/3TC/NVP 4 (2%)
TDF/3TC/EFV 24 (11%)
TDF/3TC/NVP 8 (4%)
Previous antiretroviral treatment substitution, n (%)
NRTI substitution 52 (23%)
NNRTI substitution 34 (15%)
IQR, interquartile range; d4T, stavudine; 3TC, lamivudine; EFV, efavirenz; NVP,
nevirapine; AZT, zidovudine; TDF, tenofovir; NRTI, nucleoside/nucleotide
reverse-transcriptase inhibitor; NNRTI, non-nucleoside reverse-transcriptase
inhibitor.
aBaseline CD4+ cell count was measurement closest to but prior to ART
initiation; 28 missing baseline CD4+ cell count.
bImmunological failure was defined according to WHO guidelines: fall of CD4+
cell count to baseline or below; 50% fall from on-treatment peak value; or
persistent CD4+ cell count ,100 cells/ml.
cDuration of antiretroviral failure was estimated from the date of the first viral
load .1000 copies/ml to date of genotype, unless there was a viral load ,50
copies/ml in-between, in which case the time was estimated from the next viral
load .1,000 copies/ml. If there was no viral load #1,000 copies/ml then time
was calculated from date of ART initiation.
doi:10.1371/journal.pone.0072152.t001
Table 1. Cont.
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Figure 2. NNRTI mutations.
doi:10.1371/journal.pone.0072152.g002
Figure 3. NRTI mutations, including summary of proportion with thymidine analogue mutations (TAMs).
doi:10.1371/journal.pone.0072152.g003
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year of programme scale-up [55]. Adherence monitoring tools,
predominantly reliant on patient self-reporting, have been shown
to perform poorly [46]. There are also few adherence interven-
tions of proven efficacy and so health care workers can find it
difficult not only to identify but also to address adherence
problems [56]. Antiretroviral therapy is often interwoven into
complex lives and there are often multiple barriers to adherence,
many of which are difficult, if not impossible, to overcome [57,58].
Interpretation of these results is subject to a number of
limitations. The study involved programme physicians recruiting
cases as part of routine clinical care and constraints in the number
of physicians meant that not all potentially eligible individuals
Table 2. Univariate analysis of factors associated with compromised standard second-line regimen (genotypic susceptibility score
,2).
Characteristic N % GSS ,2 Univariate OR (95% CI) p-Value
Sex
Female 156 13% 1.00 0.13
Male 61 21% 1.84 (0.85–3.99)
Age, years
18–24 8 25% 1.53 (0.27–8.51) 0.11
25–34 67 18% 1.00
35–44 92 9% 0.44 (0.17–1.14)
$45 50 22% 1.29 (0.52–3.23)
Baseline CD4+ cell count, cells/mla
,50 47 30% 1.00 0.009
50–100 41 15% 0.40 (0.14–1.18)
101–200 86 8% 0.21 (0.08–0.56)
.200 17 6% 0.15 (0.05–1.22)
Enrolment group
Routine clinic 95 (14%) 1.00
Virological failure camp 122 (16%) 1.24 (0–58–2.64) 0.58
Ever achieved virological suppression ,1000 copies/ml
No 85 18% 1.00 0.42
Yes 132 14% 0.74 (0.35–1.56)
Ever achieved virological suppression ,50 copies/ml
No 129 18% 1.00 0.19
Yes 88 11% 0.59 (0.27–1.31)
Duration of antiretroviral therapy, months
,24 20 20% 1.00 0.76
24–48 118 14% 0.63 (0.19–2.12)
.48 79 16% 0.79 (0.23–2.74)
Duration of antiretroviral failure, months
,6 14 7% 1.00 0.30
6–12 21 5% 0.65 (0.04–11.33)
13–24 63 17% 2.75 (0.33–23.27)
.24 119 17% 2.62 (0.32–21.23)
Initial antiretroviral regimen
d4T/3TC/EFV 155 17% 1.00 0.30
d4T/3TC/NVP 62 11% 0.63 (0.26–1.54)
Previous NRTI substitution
No 167 9% 1.00 ,0.001
Yes 50 36% 5.70 (2.60–12.49)
Previous NNRTI substitution
No 185 17% 1.00 0.07
Yes 32 3% 0.15 (0.02–1.17)
GSS, genotypic susceptibility score; OR, odds ratio; d4T, stavudine; 3TC, lamivudine; EFV, efavirenz; NVP, nevirapine; NRTI, nucleoside/nucleotide reverse-transcriptase
inhibitor; NNRTI, non-nucleoside reverse-transcriptase inhibitor.
a28 missing baseline CD4+ cell count.
doi:10.1371/journal.pone.0072152.t002
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could be recruited into the study. From programmatic data, as of
31 August 2012, approximately 10% (n=930) of the adults active
on first-line ART and with a viral load measurement beyond 12
months had a latest viral load .1000 copies/ml; the individuals
included in this study represent around 30% of that total. We
cannot therefore be certain that the enrolled individuals were
representative of all adults with virological failure in the
programme. There was a lack of reliable and appropriately
measured indicators of individual-level adherence and also no
information available from pharmacy records. The absence of
baseline genotyping led to assumptions that all observed drug
resistance were acquired during treatment, but this is likely to be a
reasonable assumption given that we have found no evidence as
yet of transmitted drug resistance in this community. The
definition of compromised second-line regimen was based purely
on the calculated GSS and we are prospectively following the
cohort of individuals switched to second-line therapy to explore
clinical outcomes on second-line therapy.
In summary, there are high levels of acquired drug resistance in
adults with failure of first-line antiretroviral therapy in this rural
programme. Whilst the levels of resistance are similar to those
reported from other programmes in South Africa, the long periods
of antiretroviral failure reported here give cause for concern. The
transition from an emergency response to the HIV epidemic to a
sustainable, long-term solution presents many challenges [59,60].
Management of increasingly complex drug-resistant cases through
the public health system is difficult and so programmatic strategies
for prevention and management of drug resistance are critical.
Continuous education, training and support for health care
workers, and monitoring of performance in following guidelines
are key components of any such strategy. Genotypic resistance
testing could be important in future strategies to prevent and
manage drug resistance.
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